Gene-guided hormone therapy before prostate cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread to nearby tissues or a few bones (no more than 5 spots) but not to distant organs.
- You are willing and able to have surgery to remove the prostate after the hormone therapy.
- You have not had any previous cancer treatments (except up to 28 days of certain hormone drugs).
- Your overall health is good enough to tolerate treatment and surgery, with normal blood cell counts and kidney/liver function.
- You agree to genetic testing and use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This study looks at giving rezvilutamide, a hormone therapy pill, to men with high-risk prostate cancer before they have surgery. The goal is to see if it helps make the surgery more effective and improves outcomes.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Locally Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.